{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:54:40Z","timestamp":1785772480412,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00105-026-05734-x","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:54:09Z","timestamp":1782917649000},"page":"516-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue medikament\u00f6se Therapieans\u00e4tze in der Behandlung der Hidradenitis suppurativa","New drug therapy approaches in the management of hidradenitis suppurativa"],"prefix":"10.1007","volume":"77","author":[{"given":"Andreas","family":"Pinter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"5734_CR1","unstructured":"Zouboulis CC et\u00a0al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: Treatment. J\u00a0Eur Acad Dermatol Venereol. 2024\/2025; sowie AWMF-Leitlinie 013-012."},{"key":"5734_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball\u00a0AB et\u00a0al (2016) Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 375:422\u2013434","journal-title":"N Engl J Med"},{"key":"5734_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball\u00a0AB et\u00a0al (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE). Lancet 401:747\u2013761","journal-title":"Lancet"},{"key":"5734_CR4","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball\u00a0AB et\u00a0al (2024) Bimekizumab in moderate-to-severe hidradenitis suppurativa (BE HEARD I\/II). Lancet 403:2504\u20132519","journal-title":"Lancet"},{"key":"5734_CR5","unstructured":"ClinicalTrials.gov. NCT06411899. Sonelokimab in moderate-to-severe hidradenitis suppurativa."},{"key":"5734_CR6","unstructured":"MoonLake Immunotherapeutics (2023) Phase\u00a02 MIRA and Phase\u00a03 VELA program communications."},{"key":"5734_CR7","unstructured":"MoonLake Immunotherapeutics (2026) Week 40 VELA Phase 3 data in hidradenitis suppurativa."},{"key":"5734_CR8","unstructured":"ClinicalTrials.gov. NCT05355805. Izokibep phase\u00a02b\u00a0study\u00a0in hidradenitis suppurativa."},{"key":"5734_CR9","unstructured":"ClinicalTrials.gov. NCT06993610. Tibulizumab Skin Healing in HS."},{"key":"5734_CR10","unstructured":"Zura Bio (2025) TibuSHIELD phase\u00a02\u00a0study communications."},{"key":"5734_CR11","unstructured":"ClinicalTrials.gov. NCT06895499. HB0043 bispecific IL-17A\/IL-36R antibody in HS."},{"key":"5734_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/bjd\/ljae144","volume":"191","author":"A Alavi","year":"2024","unstructured":"Alavi\u00a0A et\u00a0al (2024) Proof-of-concept study exploring spesolimab in hidradenitis suppurativa. Br J Dermatol 191:508\u2013516","journal-title":"Br J Dermatol"},{"key":"5734_CR13","unstructured":"ClinicalTrials.gov. NCT05819398. Lunsayil 1 spesolimab in HS."},{"key":"5734_CR14","doi-asserted-by":"crossref","unstructured":"Kimball AB et\u00a0al. Lutikizumab in adults with moderate-to-severe HS after anti-TNF failure. JAMA Dermatol. 2026.","DOI":"10.1001\/jamadermatol.2026.0155"},{"key":"5734_CR15","unstructured":"ClinicalTrials.gov. NCT06468228. Lutikizumab phase\u00a03 in HS."},{"key":"5734_CR16","unstructured":"ClinicalTrials.gov. NCT06603077. Abdakibart\/AVTX-009 LOTUS trial."},{"key":"5734_CR17","unstructured":"Avalo Therapeutics (2026) Phase 2 LOTUS topline results of abdakibart in HS."},{"key":"5734_CR18","unstructured":"ClinicalTrials.gov. NCT07225569. SAR445399 phase\u00a02 in HS."},{"key":"5734_CR19","unstructured":"ClinicalTrials.gov. NCT07151937. LAD191 phase\u00a02 in HS."},{"key":"5734_CR20","unstructured":"ClinicalTrials.gov. NCT06932003. LT-002-158 tablets in HS."},{"key":"5734_CR21","unstructured":"ClinicalTrials.gov. NCT07547813. LAD328 proof-of-concept study in HS."},{"key":"5734_CR22","unstructured":"Kirby JS et\u00a0al. Povorcitinib phase\u00a02 in HS. Lancet\/JAAD-related publication, 2023\/2024."},{"key":"5734_CR23","unstructured":"Incyte (2025) Positive topline results from STOP-HS1\/2 phase 3 trials of povorcitinib."},{"key":"5734_CR24","unstructured":"Ackerman LS et\u00a0al. Upadacitinib phase\u00a02 randomized study in HS. J\u00a0Am Acad Dermatol. 2025."},{"key":"5734_CR25","unstructured":"ClinicalTrials.gov. NCT05889182. STEP-UP HS phase\u00a03\u00a0study of upadacitinib."},{"key":"5734_CR26","unstructured":"ClinicalTrials.gov. NCT07228390. Ritlecitinib phase\u00a02\u00a0study in HS."},{"key":"5734_CR27","unstructured":"ClinicalTrials.gov. NCT07403968 \/ EU CTIS 2025-522831-33-00. Zasocitinib in moderate-to-severe HS."},{"key":"5734_CR28","unstructured":"ClinicalTrials.gov. NCT06799000 and NCT06840392. RECHARGE studies of remibrutinib in HS."},{"key":"5734_CR29","unstructured":"Practical Dermatology (2025) The Hidradenitis Suppurativa Therapeutic Pipeline."},{"key":"5734_CR30","unstructured":"Sanofi (2025) HS-OBTAIN brivekimig phase\u00a02a results."},{"key":"5734_CR31","unstructured":"Sanofi. NCT07170917 \/ BRIGHTEN phase\u00a02b\u00a0study\u00a0of brivekimig in HS."},{"key":"5734_CR32","unstructured":"ClinicalTrials.gov. NCT07384975. NAV-240 MAINSAIL study in HS."},{"key":"5734_CR33","unstructured":"ClinicalTrials.gov. NCT06956235. Tulisokibart\/MK-7240 phase\u00a02b in HS."},{"key":"5734_CR34","unstructured":"ClinicalTrials.gov. NCT06374212. Anifrolumab for hidradenitis suppurativa."},{"key":"5734_CR35","unstructured":"ClinicalTrials.gov. NCT06326476. Siplizumab in HS."},{"key":"5734_CR36","unstructured":"Forman S et\u00a0al. Eltrekibart phase\u00a02\u00a0trial in moderate-to-severe HS. J\u00a0Am Acad Dermatol. 2025\/2026."},{"key":"5734_CR37","unstructured":"InflaRx (2025) Positive phase 2a data for INF904 in HS and CSU."},{"key":"5734_CR38","unstructured":"Dermatology Times (2025) Oral C5aR inhibitor INF904 early efficacy report in HS."},{"key":"5734_CR39","unstructured":"Insmed (2026) Phase 2b CEDAR clinical update on brensocatib in HS."},{"key":"5734_CR40","unstructured":"ClinicalTrials.gov (2025) CIT-013 in HS; Citryll Citylights phase\u00a0IIa communication."},{"key":"5734_CR41","unstructured":"Porter ML et\u00a0al. Ruxolitinib cream in mild-to-moderate HS; randomized phase\u00a02 data. JAAD. 2025\/2026."},{"key":"5734_CR42","unstructured":"ClinicalTrials.gov. NCT06959225 \/ NCT06958211. TRuE-HS ruxolitinib cream phase\u00a03\u00a0studies."},{"key":"5734_CR43","unstructured":"ClinicalTrials.gov. NCT07049575. Maximal-use study of ruxolitinib cream in HS."},{"key":"5734_CR44","unstructured":"ClinicalTrials.gov. NCT07077902. Topical roflumilast 0.3\u202f% foam in HS."},{"key":"5734_CR45","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/jdv.19770","volume":"38","author":"CG Frederiksen","year":"2024","unstructured":"Frederiksen\u00a0CG et\u00a0al (2024) Orismilast in mild-to-severe HS: OSIRIS phase\u00a02a. J\u00a0Eur Acad Dermatol Venereol 38:920\u2013930","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5734_CR46","unstructured":"ClinicalTrials.gov. NCT06301256. Tirzepatide in moderate-to-severe HS."},{"key":"5734_CR47","unstructured":"Acosta-Madiedo AS et\u00a0al. Open-label proof-of-concept study of tirzepatide in moderate-to-severe HS. J\u00a0Drugs Dermatol. 2025."},{"key":"5734_CR48","unstructured":"ClinicalTrials.gov. NCT06857942. Tirzepatide added to ixekizumab therapy in psoriatic disease."},{"key":"5734_CR49","doi-asserted-by":"crossref","unstructured":"Lebwohl M et\u00a0al. Ixekizumab with or without tirzepatide in psoriasis and overweight\/obesity. JAMA Dermatol. 2026.","DOI":"10.1001\/jamadermatol.2026.1753"},{"key":"5734_CR50","unstructured":"ClinicalTrials.gov. NCT06361836. SBT777101 autologous Treg cell therapy in HS."}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05734-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:06:59Z","timestamp":1785769619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05734-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5734"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05734-x","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Pinter gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}